BASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna

Similar documents
Scientific and Regulatory Advice by the Federal Institute for Drugs and Medical Devices (BfArM) Guidance for Applicants (Revision 9 1 )

Scientific Advice and Protocol Assistance at the EMEA

Guidance for applicants requesting scientific advice

European Medicines Agency guidance for applicants seeking scientific advice and protocol assistance

CMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)

Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards

Procedure for handling applications for authorisation and review reports under REACH

ICTpsp I C T P O L I C Y S U P P O R T P R O G R A M M E. CIP ICT PSP Pilots A, Pilots B, Thematic Networks, Best Practice Networks, PPI Pilots

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE

Work plan for GCP Inspectors Working Group for 2018

GUIDANCE HOW TO IMPLEMENT THE PROJECT VIA THE ELECTRONIC MONITORING SYSTEM (PART II)

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Update on FDA-EMA QbD Pilot

PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR REVIEW/EVALUATION CLINICAL TRIAL APPLICATIONS FOR VACCINES AND BIOLOGICALS MALAWI

Submission of a clinical trial for access to ECRIN services Notice to the Applicant

Commission Guidelines for the implementation of the Clinical Trials Regulation NTA Ethics Oslo

Guidance on the Biocidal Products Regulation

Standard operating procedure

The place of the Certification procedure in 2017 in the EU regulatory framework and beyond. Prague, 19 September 2017

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018

Brussels, 12 June 2014 COUNCIL OF THE EUROPEAN UNION 10855/14. Interinstitutional File: 2012/0266 (COD) 2012/0267 (COD)

Questions and answers about Recycling Processes

MEDICINES CONTROL COUNCIL

Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force

Standard operating procedure

ROLLING TRAINING CALENDAR

Guide to Renewal of Veterinary Product Authorisations

Database for online accreditation process in Directorate for Accreditation of Kosovo (DAK-MIS) Abstract

ABN AINSE Post-Graduate Research Awards Conditions and Guidelines CONDITIONS

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

Guideline on good pharmacovigilance practices (GVP)

Unofficial copy not valid

STANDARD OPERATING PROCEDURE

Standard Operating Procedures (SOP) Research and Development Office

Telecommunications Authority of Trinidad and Tobago

GUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS

EDQM roadmap for electronic submissions

Asylum Migration and Integration Fund

Home Energy Saving scheme. Application Guide Version 1.1

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Joint Statement on the Application of Good Clinical Practice to Training for Researchers

Pharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist

Submission of proposals

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

General FAQ relating to e-submission for Veterinary Applications

First inspection of a Legal Representative in the EU by local authority

1. Applications must contain the following information (Article 33 of Regulation)

Guidance on the preparation of dossiers for harmonised classification and labelling (CLH) under Regulation (EC) No.

Guideline on good pharmacovigilance practices (GVP)

STANDARD OPERATING PROCEDURE

Detailed guidance for National Scientific- Technical Advice (STA) requests:

Assessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria

CALL FOR PROPOSALS FOR THE CREATION OF UP TO 25 TRANSFER NETWORKS

Guidance on the Biocidal Products Regulation

Access to Microdata in EUROSTAT.

Guideline for Applicants. Intramural Research Funding Programs Faculty of Medicine Tübingen

COMMISSION DIRECTIVE 2011/18/EU

GOVERNMENT OF THE RUSSIAN FEDERATION. DECREE of December 27, 2012 N On the Rules STATE REGISTRATION OF MEDICAL PRODUCTS

POSTGRADUATE DIPLOMA/MSc IN PHARMACEUTICAL MEDICINE

EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL. Safety of the food chain Chemicals, contaminants, pesticides

COMMISSION IMPLEMENTING REGULATION (EU)

MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC

Biocidal product regulation the changes to come

1 The EU Harmonised technical ectd guidance version 4.0

FULL PROJECT PROPOSAL

BRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER

Open call for proposals VP/2004/021. Initiatives to promote gender equality between women and men, including activities concerning migrant women

Q11 Development and Manufacture of Drug Substances--Questions and Answers

1. Introduction, purpose of this Standard Operating Procedure (SOP)

ICH Topic Q4B Annex 6 Uniformity of Dosage Units General Chapter. Step 3

Incentive Guidelines Research and Development - Tax Credits INDUSTRIAL RESEARCH PROJECTS; EXPERIMENTAL DEVELOPMENT PROJECTS; INTELLECTUAL PROPERTY

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme

INVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT. Susanna Palkonen, EPF Board Member

NHS Lanarkshire Policy for the Availability of Unlicensed Medicines

NATIONAL ACCREDITATION POLICY FOR HEALTHCARE FACILITIES

R. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager

Guidance on Scientific Research and Development (SR&D) and Product and Process Orientated Research and Development (PPORD)

This document provides useful instructions and tips to help you prepare your scholarship application.

Home Energy Saving (HES) scheme - Homeowner Application Form Version 10.0

Grant Requirements Dutch Kidney Foundation as from 1 January 2017

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

The Dialogue Facility THE DIALOGUE FACILITY Bridging Phase Guidelines and Criteria for Support

Call: Graduate school in energy systems

Guidelines on Retroactive CTI Grant Funding for R&D consortiums

Annex. Provisions on auditing notified conformity assessment bodies in the framework of Article 34 3 of the Agency Regulation 1

INNOFUND GUIDELINE FOR APPLICANTS

Version Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13

NAMIBIA MEDICINES REGULATORY COUNCIL MINISTRY OF HEALTH AND SOCIAL SERVICES

CHPS Verified Program User Guide. Version 2.0. Effective December 12, 2013

NABET Criteria for Food Hygiene (GMP/GHP) Awareness Training Course

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Intertek Health, Environmental & Regulatory Services

Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions

MATERIAL RESOURCES PROGRAMME FOR INSTITUTIONS OF HIGHER EDUCATION IN DEVELOPING COUNTRIES*

Standard Operating Procedure:

Overview of the IMB s. Good Clinical Practice. Deirdre O Regan GCP/Pharmacovigilance. GCP Seminar Dublin, 27 th January 2010.

Working document QAS/ RESTRICTED September 2006

GRANT AGREEMENT FOR AN ACTION ACTION 2 - ERASMUS MUNDUS PARTNERSHIPS Financing exclusively by lump sum contribution(s) and/or unit contribution(s)

Transcription:

This guidance document is intended to provide applicants with detailed information on the operational procedure of National Scientific Advice (NASA) by the Austrian Federal Office for Safety in Health Care (BASG). Applicants are kindly requested to follow the recommendations provided below to enable an efficient and timely advice procedure. 1. Introduction BASG offers National Scientific Advice to applicants, addressing scientific questions arising during the development of. A NASA can be requested both before and after authorisation of a medicinal product. The following topics are in the scope of an advice procedure: Manufacturing and quality of (chemical, pharmaceutical, biological development) Planning and execution of nonclinical trials (e.g., pharmacology, toxicology) Planning and execution of clinical trials Biostatistics Pharmacovigilance and risk management 2. General guidance The basis for providing Scientific Advice are the Austrian Medicines Act (Arzneimittelgesetz, AMG) and applicable European and international directives and guidelines (e.g., EMA, EC, ICH) in their current version or, if relevant to the discussion, draft documents under revision by the scientific community or competent bodies. BASG offers Scientific Advice in face-to-face discussion meetings. In addition to clearly specified questions, the applicant is requested to detail his position and to provide an up-to-date background documentation to support the issues of discussion (see also section 3.3). During the Scientific Advice procedure, only questions that are accompanied by detailed study outlines or development programs will be discussed. Regulatory questions and questions as to whether specific study results are suitable to obtain marketing authorisation for the product in question, are outside the scope of the NASA process. Also, please keep in mind that only questions submitted in advance can be discussed with during the meeting, which has a maximum duration of 2 hours. In the interest of the Applicant, the number and scope of the questions should therefore be adequate for discussion within a 2-hour time frame. The Scientific Advice is associated with fees and will be offered subject to availability of resources at the time the questions are submitted. Follow-up Scientific Advice, i.e., advice given subsequent to previous advice on the same product or question, is in principle possible. A prerequisite for follow-up Scientific Advice is that new plans (e.g. updated study protocols) or new scientific knowledge have become available, thus justifying an additional advice procedure. L_BGA_VIE_CASE_B65_07 Valid from: 11.01.2017 1 von 6

3. Overview of the Scientific Advice procedure Applicant sends email including Application form List of Questions, including a justification of the Applicant s position, to the following email-address: scientificadvice@ages.at. Within 4 business days after receipt of documents BASG Validates the application Checks for availability of resources and expertise Prepares and mails a Letter of Agreement, including: Formal approval Notification of the earliest possible meeting date Notification of the latest possible date for the submission of the final dossier (i.e., complete documentation for review) Fee calculation If applicable, Letter of Refusal Within 5 business days after notification of meeting date 3 weeks before the meeting at the latest 1 business day before the meeting at the latest Scientific Advice meeting with Applicant Applicant sends a scanned copy of the legally signed Letter of Agreement (confirmation of meeting date and acceptance of fee) by email to: scientificadvice@ages.at Alternatively, the applicant withdraws the request in writing. Applicant submits dossier electronically (by email to scientificadvice@ages.at or on CD-Rom) plus 4 paper copies Applicant sends an electronic version of the presentation prepared for the meeting: by email to: scientificadvice@ages.at Applicant presents the questions supplies 5 paper copies of the presentation as handouts Question-by-Question discussion during the presentation Within 5 business days after the meeting Within 10 business days after receipt of the draft meeting Applicant prepares draft meeting minutes and sends these to BASG/AGES by email: scientificadvice@ages.at BASG / AGES experts review the draft meeting minutes and prepare the final meeting minutes. L_BGA_VIE_CASE_B65_07 Valid from: 11.01.2017 2 von 6

minutes mail a hard copy of the final meeting minutes to the Applicant. 3.1. Application All applications have to be made in writing (email to: scientificadvice@ages.at). The applicant is asked to use application form F_Z105_Antrag_NASA, which is available for download from www.basg.gv.at/en/medicines/before-authorisation/national-scientific-advice Also, the applicant is asked to attach a List of Questions, including a justification of the applicant s position. 3.1.1. Application form The following explanations might be helpful for completion of the application form: Item 2 Item 5 Items 6 and 7 Item 8 Item 9 Items 10 and 11 Item 14 Name and further details of company/organisation/consortium applying for Scientific Advice If the application is submitted by a legal representative of the Applicant (e.g., a consultant), a letter of authorisation specific to the consultant and procedure in question should be submitted together with the complete dossier. If applicable, the Applicant is asked to attach any minutes from former advice procedures with other regulatory agencies. Also, please indicate whether available documents are in draft or final status. More than one box can be ticked. At the time of application, the ATC code and/or indication might not be unequivocally clear. In this case, provisional information should be provided. If the drug/product is approved inside or outside the EU, the Applicant is asked to attach (to the final dossier) a short summary of the approval status in each country and the wording of the approved indication(s). Please compile a list of all documents attached to the application form. 3.1.2. List of Questions When submitting the application form, the applicant is asked to attach a document containing a List of Questions, including justifications of the applicant s positions. A template for this List of Questions is available for download from www.basg.gv.at/arzneimittel/vor-der-zulassung/nationalewissenschaftliche-beratung. However, the applicant is free to choose another format. L_BGA_VIE_CASE_B65_07 Valid from: 11.01.2017 3 von 6

During validation of the application, the scope and number of questions will determine the further course of the advice procedure. First, a decision will be made whether the proposed set of questions provides a meaningful basis for the advice procedure. Second, the need for or availability of expertise will be evaluated internally, and a provisional date for the advice meeting will be chosen. During the advice meeting, only questions actually contained in the List of Questions will be addressed. Should it become necessary to add to or change the set of questions after validation of the application, please contact BASG/AGES (scientificadvice@ages.at) to discuss whether an updated version of the List of Questions may still be submitted for the scheduled advice meeting or whether the meeting should be postponed. Please note that, in the absence of a pre-meeting notification, any new information first presented during the Scientific Advice meeting cannot be taken into consideration. Questions should be clear and specific, and one question should not mix different issues. The number of questions should be chosen in such a way that all issues can be covered in a 2-hour meeting. The goal of the advice procedure is to discuss the plans and proposals submitted by the applicant. Therefore, each question should be accompanied by a summary of the plans and proposals developed by the applicant. In some cases, it may be useful to present alternative scenarios addressing a specific issue of the development process. 3.2. Letter of Agreement Within 4 business days after receipt of the request for Scientific Advice, BASG will formally validate the application. Please note that a request for Scientific Advice can only be accepted subject to resources available at BASG/AGES. As a rule, requests for Scientific Advice will be dealt with in the order of receipt. The applicant will be notified in writing on whether the application has been accepted or refused. Final acceptance of an application is subject to submission of the final dossier within the specified time frame. A Letter of Agreement will be transmitted to the applicant. This letter will specify both a date for the Scientific Advice meeting and the latest acceptable date for submission of the final dossier. Furthermore, a fee calculation will be included (see also section 4). The applicant is asked to send a scanned copy of the legally signed Letter of Agreement to BASG / AGES by email (scientificadvice@ages.at. By doing so, the applicant declares acceptance of the estimated costs of the Scientific Advice (see also section 4). L_BGA_VIE_CASE_B65_07 Valid from: 11.01.2017 4 von 6

3.3. Dossier and List of Participants The dossier should contain information needed to address the questions asked. The structure and content should be suitable to the questions submitted. Content of the dossier: List of Questions, including the position of the Applicant Background information on the drug substance/product and indication(s) Any relevant literature referenced in the dossier List of the Applicant s participants (including their functions) If applicable, minutes of Scientific Advice obtained from other competent authorities If applicable, relevant documents on the authorisation status of the drug substance/product in other countries If applicable, other relevant documents, e.g., study protocols If applicable, letter of authorisation (for applications submitted by a legal representative of the Applicant) In case of changes to the list of participants after the application has been submitted, please inform BASG/AGES by email in a timely manner. The dossier should be submitted electronically (by email: scientificadvice@ages.at or on CD-Rom) and in the form of 4 sets of paper hardcopies no later than 3 weeks before the agreed Scientific Advice meeting date. 3.4. Advice meeting at BASG/AGES The advice meeting is scheduled for a maximum of 2 hours. The meeting will be chaired by an BASG representative. After a round of welcome and introduction, the applicant shall give a presentation of the background and issues of the advice request. The presentation should be given in such a manner that sufficient time is available for discussion. Experience has shown that discussing each question immediately after it has been presented by the applicant is the most efficient approach ( questionby-question principle). The applicant is asked to submit the file for the presentation no later than one day before the advice meeting (email to scientificadvice@ages.at). Furthermore, the applicant is asked to provide and bring along 5 sets of handouts (hardcopy) for meeting participants. It should be noted that, aside from BASG/AGES experts assigned to the project, BASG/AGES assessors or administrators not directly involved in the procedure may attend the advice meeting for training or information purposes. As a matter of course, all attending participants are bound to strict confidentiality. L_BGA_VIE_CASE_B65_07 Valid from: 11.01.2017 5 von 6

3.5 Meeting minutes The applicant is asked to prepare a draft version of the meeting minutes. To permit efficient finalisation of the advice procedure, the applicant is asked to email the draft in the form of an electronic MS Word file no later than 5 working days after the meeting to scientificadvice@ages.at. The meeting minutes should summarise both the discussion and the answers given by BASG/AGES representatives. There is no need to present the detailed course of the discussion. The minutes should include: date, place and duration of meeting, name and contact details of applicant, name of product (if available), active ingredient, and a list of participants. BASG will review the draft minutes and may change them as deemed appropriate to produce a final version of the meeting minutes. This final version will be sent to the applicant within 10 working days after receipt of the draft version. The Applicant will receive both an electronic (PDF) version as well as a signed and dated hardcopy version of the final meeting minutes. 4. Fees Each Scientific Advice requires payment of a fee. For the valid fee please refer to http://www.basg.gv.at/en/about-us/fees/ or http://www.basg.gv.at/en/about-us/fees/officialannouncements. If the advice meeting has to be cancelled for reasons attributable to the applicant or if the applicant fails to submit the final application in time, i.e., no later than 3 weeks before the Scientific Advice meeting, BASG shall be entitled to invoice for services already rendered. L_BGA_VIE_CASE_B65_07 Valid from: 11.01.2017 6 von 6